The Coalition of State Bioscience Institutes (CSBI) joined InnovATEBIO at National Summit to Address Booming Bioscience Industry’s Talent Needs

Summit convened diverse stakeholders in a state ecosystem approach aimed at meeting industry’s urgent workforce gaps

June 30, 2023 | WASHINGTON–( BUSINESS WIRE)–Coalition of State Bioscience Institutes (CSBI) and InnovATEBIO convened a national Summit this week at the National Academies of Sciences in Washington, D.C., tasked with developing workforce strategies designed to sustain U.S. leadership in life sciences innovation. Both national organizations and their multi-state members helped to comprise over 250 attendees for the National Science Foundation- (NSF-)supported  Envisioning the Next Bioscience Workforce Summit , which brought together thought leaders from industry, academia, and government to forecast the continuing wave of discoveries and corresponding talent needs from the industry’s biopharmaceutical, biomedical device, bioprocessing, bioengineering, synthetic biology, and food production subsectors.

INNOVATEBIO + CSBI logo lockup

The first-of-its-kind assembly of diverse public and private stakeholders were brought together by InnovATEBIO, an NSF-funded National Advanced Technology Education Center that supports biotechnology education through its robust network of community colleges, and CSBI, a national coalition of bioscience trade associations and institutes who are committed to delivering industry-led workforce development programs. The collaboration between CSBI and InnovATEBIO has intensified over the last five years as part of an effort to address an outsized demand for talent by the life sciences industry and to open access to careers for a broad and diverse talent base.

Inspired by the innovation forecasts from leaders from the industry’s diverse segments, the Summit’s second day catalyzed state teams, comprised of stakeholders from industry, academia and workforce and economic development organizations, to collaborate on strategic solutions to address workforce gaps in their states.

“The bioscience industry’s workforce challenges are too urgent for any single stakeholder to try and address alone,” said Linnea Fletcher, Executive Director of the InnovATEBIO National Biotech Education Center. “We know that some states are doing an admirable job of bringing their community college and other academic partners together with industry, trade associations and governmental agencies to develop targeted programs that both meet and stay abreast of the industry’s rapidly evolving talent needs. We hope the Summit and its aftermath will provide more states with tools to develop similar strategic collaborations that will address gaps in their own states, a clear win-win for the industry and the highly trained students coming out of our ATE and other programs.”

“What I don’t think many recognize is how significantly many of these ATE and other academic programs can – and are – rapidly responding to urgent calls from bioscience employers for highly skilled technicians,” said Liisa Bozinovic, CSBI Chair and Executive Director of the Oregon Bioscience Association. “These programs are not only meeting companies’ immediate talent needs, but also offering a diverse set of students an accessible and rewarding pathway with multiple options for career and educational growth. That is what we sought to do with this Summit – to help more states develop the partnerships and funding to address gaps in their own regions.”

InnovATEBIO and its partners will continue to support the work of the state teams in the aftermath of the Summit to both broaden and deepen this important work.

For additional information on the Summit, click  here.

About the Coalition for State Biotech Institutes (CSBI)

The Coalition for State Biotech Institutes is dedicated to ensuring America’s leadership in bioscience innovation by delivering industry-led life sciences education and workforce development programs through a nationally coordinated effort. Programs are uniquely positioned for the life sciences industry to deliver, replicable in states across the U.S., extensible to other STEM industry sectors and are fully aligned with Next Generation Science Standards (NGSS). Learn more at  www.csbioinstitutes.org  where you can download our  2023 Life Science Workforce Trends Report.

About InnovATE BIO , the National Biotechnology Education Center:  InnovATE BIO  is supported by a five-year Advanced Technical Education (ATE) grant to advance biotechnology technician education nationally through cutting-edge professional training for instructors and share the best practices among community college programs, administrators, trade organizations, and industry. The Center seeks to develop a collaborative infrastructure that supports innovation and promptly addresses the needs of the biotechnology community. InnovATE BIO  aims to coordinate ATE-funded biotechnology projects to identify opportunities to generate partnerships and collaborations that will accelerate innovation in biotechnology education. In addition to these efforts, it seeks to monitor and address emerging biotechnology industry and technician workforce trends.

Follow Innov ATEBIO  on  Facebook,  LinkedIn, and  Twitter  at #InnovATEBIO to stay current on biotechnology education in community colleges. View posts at #EnvisioningBioscience for the Envisioning the Next Bioscience Workforce Summit.

Contacts

Maria Thacker, Georgia Bio
mthacker@gabio.org
404-920-2042

November 4, 2026
CEO Note: A New Political Landscape, A Continued Commitment to Georgia Life Sciences Georgia's 2026 election results mark a historic shift in the state's political landscape, setting the stage for a new administration, new statewide leadership, and a potentially changed balance of power in the General Assembly as we approach the 2027 legislative session. At the national level, Democrats won control of both chambers of Congress , creating a new dynamic for federal policymaking. With the presidency remaining under Republican leadership, the coming years will require bipartisan cooperation to advance legislation. Changes in congressional leadership and committee oversight could significantly affect healthcare, federal research funding, FDA policy, drug pricing, and patient access. The most significant changes for our industry, however, are happening here in Georgia. Keisha Lance Bottoms' victory in the gubernatorial race marks a historic transition in state leadership, ending more than two decades of Republican control of the Governor's Office. She will also become the first Black woman elected governor in U.S. history. Democrats also swept Georgia's statewide executive offices , including lieutenant governor, attorney general, secretary of state, and the commissioners responsible for agriculture, labor, and insurance. These leadership changes create new opportunities for engagement on the policies and investments that shape Georgia's economy. In the General Assembly, Democrats made substantial gains and appear positioned to take control of the Georgia House of Representatives , pending final results in several close races. Republicans retained a narrowed majority in the State Senate. This potentially divided legislative environment will require thoughtful engagement and collaboration across party lines. We can also expect considerable turnover in the General Assembly, with dozens of new legislators beginning their terms in January. Along with a new Governor and incoming administration, this creates an important opportunity to introduce policymakers to Georgia's life sciences industry, its economic contributions, and its potential for future growth. What Does This Mean for Georgia's Life Sciences Industry? Life sciences is an economic development priority that should transcend party lines. Our industry's growth depends on a combination of sound public policy, private investment, research, workforce development, infrastructure, and a business environment that encourages innovation and commercialization. As Georgia establishes its new leadership priorities, several areas will be particularly important: Economic Development and Manufacturing: Positioning Georgia to attract and retain biopharmaceutical, biotechnology, and MedTech companies while advancing the infrastructure and capabilities needed to support scale-up manufacturing. Research and Commercialization: Strengthening connections between Georgia's research institutions, emerging companies, investors, and industry partners to move discoveries from the laboratory into commercial applications. Workforce Development: Expanding investment in technical education, apprenticeships, and industry-aligned training to prepare Georgians for the growing range of life sciences careers. Capital and Investment: Improving access to capital and supporting programs that help Georgia-based companies grow, commercialize technologies, and remain competitive. Healthcare Innovation and Patient Access: Supporting an environment that encourages medical innovation, advances research, and improves patient access to new treatments and technologies. These priorities align directly with Pathways & Partnerships: A Roadmap for Georgia's Life Sciences Sector , our ten-year strategy to position Georgia as a leading scale-up manufacturing hub in the Southeast. Georgia enters this transition with both an opportunity and a clear need to strengthen its competitiveness in life sciences. The recently released BIO/TEConomy report highlights the industry's significant contributions, including more than 42,600 jobs across over 4,200 establishments, while reinforcing the opportunity for Georgia to accelerate growth relative to other states. Our Roadmap provides a foundation for working with policymakers to turn these opportunities into sustained investment, stronger industry partnerships, and high-quality jobs throughout Georgia. GLS's Role Moving Forward For Georgia Life Sciences, this transition reinforces the importance of our role as the industry's statewide voice and convener. We will be intentional about building relationships with the incoming administration, new legislative leadership, returning legislators, and state agencies. We must ensure that policymakers understand not only the healthcare implications of our industry, but also its broader economic impact: high-quality jobs, significant research investment, advanced manufacturing, innovation, and opportunities for communities across Georgia. At the federal level, we will continue working with our national partners and Georgia's congressional delegation to advocate for policies that sustain research and innovation, support a predictable regulatory environment, strengthen American biomanufacturing, and advance patient access. With a new administration and many new legislators, we have an opportunity to establish a stronger understanding of what it takes to build and sustain a competitive life sciences ecosystem. That means bringing industry leaders to the table, communicating our priorities, identifying areas of bipartisan alignment, and advocating for policies that support long-term growth. Our industry's success requires a long-term commitment that extends beyond any election cycle or administration. The political landscape may change, but our commitment to advancing Georgia's life sciences industry remains constant. We look forward to working with leaders on both sides of the aisle to ensure Georgia continues to be a place where life sciences companies can innovate, invest, manufacture, and grow.
October 30, 2026
For Georgians living with serious and rare diseases, how quickly and predictably a new treatment moves through U.S. Food and Drug Administration (FDA) review can make a real difference. That predictability also matters to the researchers and businesses that make up Georgia’s growing life sciences sector. Both depend in large part on the Prescription Drug User Fee Act (PDUFA), a longstanding bipartisan program that Congress needs to reauthorize by 2027. How PDUFA Works Since 1992, PDUFA has allowed the FDA to collect user fees from biopharmaceutical companies to supplement the agency’s resources for reviewing new medicines. In exchange, the FDA commits to clear, predictable review timelines. The agency’s standards for safety and efficacy remain unchanged. By providing additional resources and establishing clear performance goals, PDUFA helps ensure patients can access new treatments in a more timely and predictable manner. The result of PDUFA have been significant. Before PDUFA, FDA reviews often took more than two years. Today, the median review time is 10 months for standard applications and 8 months for priority applications. In 2025, nearly 70% of new medicines were approved in the U.S. before any other country. What’s at Stake in 2027 Congress reauthorizes PDUFA every five years. The current agreement, PDUFA VII, expires September 30, 2027. Timely reauthorization is critical to maintaining the FDA’s review capacity, preserving regulatory predictability, and ensuring patients continue to benefit from medical innovation. Georgia stakeholders recently came together to talk through what that means here at home. On October 28, Georgia Life Sciences, the MTS Sickle Cell Foundation, and Georgia First hosted “PDUFA: How Medicines Reach People,” a lunch-and-learn at Brookhaven City Centre. Patient advocates, congressional staff, and business and academic leaders heard from Nick Magallanes of Todd Strategy Group, Natalie Crawford of Georgia First, Maria Thacker-Goethe of Georgia Life Sciences, and Mapillar Dahn of the MTS Sickle Cell Foundation. What We Heard At the event, speakers came at PDUFA from different angles, but the common thread was how the program affects Georgians. Mapillar Dahn of the MTS Sickle Cell Foundation stressed that patients need to remain at the center of conversations. As a mother of three daughters with Sickle Cell Disease, Mapillar stressed that she wants the FDA to have what it needs to carry out a thorough review without unnecessary delays. The confidence families place in a treatment depends in part on confidence in that process. Natalie Crawford with Georgia First and Mended Hearts spoke about the need for a fully resourced FDA so that Georgia patients have access to innovative treatments and also for a healthy Georgia economy. Additionally, Maria Thacker-Goethe spoke to what PDUFA reauthorization means for Georgia’s booming life sciences sector. She warned that without PDUFA reauthorization, research across the board will be stifled – ranging from devastating impacts to small startups to significant delays in investments and research. Part of a National Conversation As Congress prepares for the 2027 reauthorization, conversations like these help bring together patients, advocates, and community leaders to highlight the real-world importance of the program. Decisions made in this reauthorization cycle will shape FDA resources and review timelines nationwide. By reauthorizing PDUFA on time, Congress can make sure the FDA can keep reviewing new medicines efficiently and patients in Georgia and across the country can get the treatments they need. 
October 29, 2026
Increasingly high bond rates are having important implications for the U.S. life sciences ecosystem – and underscore the role of mergers and acquisitions (M&A) and other pro-competitive partnerships in advancing innovation. The upshot. Developing a new medicine requires significant and sustained investment over many years. This makes the life sciences industry especially sensitive to changes in the cost and availability of capital. With financial conditions tightening, a predictable environment for life sciences M&A is critical to sustaining investment in the next generation of cutting-edge treatments and cures. Why bond rates matter. It can cost billions and take more than a decade to bring a new treatment or cure to patients. Often, these companies operate without a profit and rely on outside investment (such as venture capital) to finance this high-stakes journey. When relatively low-risk investments like U.S. Treasury bonds offer stronger returns, investors need significantly greater potential returns to justify betting on riskier, long-term investments, such as drug development. The cost to early-stage life sciences investment. For emerging life sciences companies, less available capital can mean fewer resources to advance promising science and fewer new cures reaching patients. Research from NBER estimated that an unexpected one-percentage-point increase in interest rates reduces R&D spending across industries by approximately 1–3% and venture investment by roughly 25% over the following one to three years. M&A as an investment incentive. A healthy M&A environment provides a critical incentive for investors to support high-risk science by offering a potential exit. The prospect of an acquisition allows investors to realize returns from financing early-stage research – and reinvest that capital in the next generation of treatments and cures. M&A helps advance promising innovation. M&A is similarly vital to turning the promising science that attracted investment into approved medicines for patients. Emerging companies contribute specialized scientific knowledge and innovative drug candidates – but often depend on partnerships with larger, more established companies to access the clinical-development expertise, regulatory capabilities and infrastructure needed to bring medicines to patients. The evidence reinforces this complementary relationship. Findings from Cornerstone Research show that drug projects acquired from smaller companies by firms with prior launch experience were three times more likely to launch – and five times more likely to launch as novel drugs – than projects acquired by another small firm. A predictable pathway forward. When higher bond rates raise the bar for investing in innovation, policymakers should avoid adding unnecessary barriers to an already challenging investment environment. A predictable and balanced approach to merger enforcement can help preserve life sciences M&A as a vital pathway for transforming promising scientific discoveries into new medicines for patients. Source: Importance of Life Sciences M&A Amid Rising Interest Rates - Partnership for the U.S. Life Science Ecosystem (PULSE)
MORE POSTS